摘要
冠状动脉粥样硬化性心脏病是威胁人类健康的主要疾病之一,会引起急性心肌梗死。目前针对心肌梗死,最有效的治疗是溶栓或经皮冠脉介入术治疗,恢复缺血冠状动脉的血流,减少梗死面积。然而,在治疗的同时,会发生缺血再灌注损伤和心肌细胞死亡。细胞死亡的方式研究较多的主要有两种:细胞凋亡和细胞坏死。后者包括程序性坏死和细胞焦亡。两种死亡形式与细胞凋亡不同,两者在形态学上有相同点,但在发生和执行机制上有所不同。这两种死亡方式贯穿于心肌缺血再灌注损伤的发生过程中。现就有关心肌缺血再灌注损伤的病理生理,以及程序性坏死和细胞焦亡的发生执行分子机制做一综述,其中NOD样受体家族含吡啶结构域、胱天蛋白酶和gasdermin D关键靶点有望为缺血心肌保护提供新的治疗思路。
Coronary atherosclerotic heart disease is one of the main diseases that threatening human health and can cause acute myocardial infarction.At present,the most effective treatment for myocardial infarction is thrombolytic therapy,or percutaneous coronary intervention,to restore the blood flow of ischemic coronary arteries and reduce the ischemic area.However,at the same time of treatment,ischemia-reperfusion injury and myocardial cell death may occur.There are two main ways of cell death:apoptosis and necrosis.The latter includes necroptosis and pyroptosis.This two forms of death are different from apoptosis,they are similar in morphology,but different in mechanism of occurrence and execution.These two modes of death are involved in the process of myocardial ischemia-reperfusion.This paper reviews the pathophysiology of myocardial ischemia-reperfusion injury and the molecular mechanism of the necroptosis and apoptosis.Nucleotide-mediated oligomerization domain-like receptor family pyrin domain containing,caspase and gasdermin D,these key targets are expected to provide a new therapeutic approach for the protection of ischemic myocardium.
作者
郭双
邢栋
吕勃
GUO Shuang;XING Dong;LYU Bo(Department of Cardiology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150081,Heilongjiang,China)
出处
《心血管病学进展》
CAS
2020年第12期1255-1259,1289,共6页
Advances in Cardiovascular Diseases
基金
国家自然基金青年科学基金(81400296)
中国博士后科学基金(2017M61139)
黑龙江省留学归国人员科学基金(LC201434)。
